dabigatran + aspirin

Dabigatran + aspirin is a combination therapy consisting of two pharmacologically distinct agents used together for specific cardiovascular indications. Dabigatran is an oral direct thrombin inhibitor (anticoagulant) that prevents the formation of blood clots by inhibiting thrombin, a key enzyme in the coagulation cascade. Aspirin (acetylsalicylic acid) is an antiplatelet agent that irreversibly inhibits cyclooxygenase-1 (COX-1), thereby reducing the synthesis of thromboxane A2 and inhibiting platelet aggregation. This combination may be prescribed in patients with atrial fibrillation who also have comorbid conditions such as coronary artery disease or diabetes, where both anticoagulation and antiplatelet effects are desired. However, combined use significantly increases the risk of bleeding events, particularly in elderly patients or those with additional risk factors[1][4][6]. The combination should only be used under careful medical supervision and typically for limited durations to minimize adverse outcomes.

Brand names

Pradaxa + Aspirin

Other names

dabigatran etexilate + acetylsalicylic acid